Home/Pipeline/Batoclimab (HBM9161)

Batoclimab (HBM9161)

Myasthenia Gravis

Phase 3Out-Licensed

Key Facts

Indication

Myasthenia Gravis

Phase

Phase 3

Status

Out-Licensed

Company

Harbour BioMed

About Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Metabolic Diseases

Other Myasthenia Gravis Drugs

Drug	Company	Phase	Status
Nipocalimab	johnson-and-johnson-innovative-medicine	Phase 3	Active
Myasthenia Gravis Live CBA Panel	Neurocode	Commercial	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
KYV-101 (mivocabtagene autoleucel)	Kyverna Therapeutics	Phase 2	Recruiting